Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.
暂无分享,去创建一个
[1] S. Cole,et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.
[2] F. DuBru,et al. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. , 1998, Molecular pharmacology.
[3] A. Duncan,et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.
[4] D. Hipfner,et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.
[5] T. Furukawa,et al. Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. , 1997, Molecular pharmacology.
[6] F. Baas,et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Lozzio,et al. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.
[8] C. Higgins,et al. ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.
[9] N. Mulder,et al. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. , 1987, Cancer research.
[10] F. Russel,et al. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. , 1999, Molecular pharmacology.
[11] D. Keppler,et al. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.
[12] T. Uchiumi,et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2) , 1999, FEBS letters.
[13] D. Ettori,et al. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. , 1999, Biochimica et biophysica acta.
[14] W. Priebe,et al. P‐glycoprotein‐mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells , 1994, FEBS letters.
[15] J. Lankelma,et al. The effect of glutathione on the ATPase activity of MRP1 in its natural membranes , 2000, FEBS letters.
[16] D. Keppler,et al. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. , 1996, The Biochemical journal.
[17] A. Garnier-Suillerot,et al. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. , 1994, European journal of biochemistry.
[18] F. Frézard,et al. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. , 1991, European journal of biochemistry.
[19] P. Jansen,et al. ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.
[20] N. Kaplowitz,et al. The use of monochlorobimane to determine hepatic GSH levels and synthesis. , 1990, Analytical biochemistry.
[21] V. Ling,et al. Mechanism of multidrug resistance. , 1988, Biochimica et biophysica acta.
[22] F. DuBru,et al. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. , 1996, Molecular pharmacology.
[23] S. Cole,et al. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. , 1996, The Journal of biological chemistry.
[24] S. Cole,et al. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.
[25] G. Kruh,et al. © 1999 Cancer Research Campaign Article no. bjoc.1999.0527 MOAT-E (ARA) is a full-length MRP/cMOAT subfamily , 2022 .
[26] J. S. Brand,et al. Assay of picomole amounts of ATP, ADP, and AMP using the luciferase enzyme system. , 1975, Analytical biochemistry.
[27] R. Evers,et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione , 1999 .
[28] S. Cole,et al. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. , 1999, Biochimica et biophysica acta.
[29] R. Scheper,et al. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. , 1995, British Journal of Cancer.
[30] F. Frézard,et al. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells. , 1991, Biochimica et biophysica acta.
[31] F. Baas,et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Garnier-Suillerot,et al. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. , 2000, European journal of pharmacology.
[33] A. Garnier-Suillerot,et al. Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. , 1994, Biochimica et biophysica acta.